| P50 | author | D.J. Mooney | Q67472236 |
| P2093 | author name string | Hua Wang | |
| P2860 | cites work | Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose | Q47301856 |
| | Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events | Q47367962 |
| | Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy | Q47447851 |
| | Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. | Q47681829 |
| | Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. | Q47830138 |
| | Spatial Targeting of Tumor-Associated Macrophages and Tumor Cells with a pH-Sensitive Cluster Nanocarrier for Cancer Chemoimmunotherapy. | Q48165120 |
| | Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. | Q48243270 |
| | Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment | Q48962570 |
| | Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads | Q50039410 |
| | Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation | Q50322302 |
| | A facile approach to enhance antigen response for personalized cancer vaccination. | Q50532509 |
| | Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. | Q51887034 |
| | A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy. | Q52565193 |
| | The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. | Q52720460 |
| | Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. | Q53110220 |
| | PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. | Q53255741 |
| | A carbon nanotube-polymer composite for T-cell therapy. | Q53482969 |
| | Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. | Q54251457 |
| | Biomaterial-based vaccine induces regression of established intracranial glioma in rats. | Q55463511 |
| | A Protective Vaccine Delivery System for In Vivo T Cell Stimulation Using Nanoengineered Polymer Hydrogel Capsules | Q56769270 |
| | Cancer immunotherapy meets biomaterials | Q86501820 |
| | In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy | Q87841767 |
| | Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells | Q23909978 |
| | Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy | Q26782566 |
| | Immune Checkpoint Blockade in Cancer Therapy | Q26830509 |
| | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| | Synthetic Nanoparticles for Vaccines and Immunotherapy | Q28085375 |
| | Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 |
| | Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 |
| | The future of immune checkpoint therapy | Q28259862 |
| | Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice | Q28486624 |
| | Macrophage plasticity and polarization: in vivo veritas | Q29547620 |
| | PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 |
| | Programming the magnitude and persistence of antibody responses with innate immunity | Q30400144 |
| | Biopolymer implants enhance the efficacy of adoptive T-cell therapy. | Q30614247 |
| | Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients | Q33586724 |
| | Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer | Q33606107 |
| | In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells | Q33635879 |
| | In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer | Q33671654 |
| | In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes | Q33716478 |
| | Structure-based programming of lymph-node targeting in molecular vaccines | Q33800766 |
| | Cytokine-secreting tumor cell vaccines | Q34046851 |
| | Therapeutic cell engineering with surface-conjugated synthetic nanoparticles | Q34112602 |
| | Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 |
| | Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. | Q34428078 |
| | Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis | Q34444291 |
| | Neoantigens in cancer immunotherapy. | Q34470074 |
| | SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions | Q34518758 |
| | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 |
| | Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. | Q34531618 |
| | Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses | Q34802680 |
| | Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. | Q35053924 |
| | Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle | Q35537413 |
| | 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice | Q35863346 |
| | Targeting Dendritic Cells in vivo for Cancer Therapy | Q35928270 |
| | Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity | Q35983565 |
| | Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients | Q36060333 |
| | Microneedles for drug and vaccine delivery | Q36164749 |
| | Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. | Q36170378 |
| | First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients | Q36341084 |
| | Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy | Q36391595 |
| | Injectable, Pore-Forming Hydrogels for In Vivo Enrichment of Immature Dendritic Cells | Q36470551 |
| | Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication | Q36540614 |
| | Injectable cryogel-based whole-cell cancer vaccines | Q36608119 |
| | Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach | Q36612202 |
| | Beyond antigens and adjuvants: formulating future vaccines | Q36618500 |
| | Overview of tumor cell-based vaccines | Q36684485 |
| | Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy | Q36696647 |
| | Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity | Q36710977 |
| | Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells | Q37097777 |
| | Dendritic cell targeted vaccines: Recent progresses and challenges | Q37135259 |
| | Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy | Q37191649 |
| | 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy | Q37257276 |
| | The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer | Q37423348 |
| | Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells | Q37515801 |
| | Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues | Q37543916 |
| | Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia | Q37592070 |
| | Microfluidic applications of magnetic particles for biological analysis and catalysis | Q37644451 |
| | Designer vaccine nanodiscs for personalized cancer immunotherapy | Q37730767 |
| | Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. | Q37731672 |
| | Therapeutic vaccines and cancer: focus on DPX-0907. | Q38193430 |
| | Therapeutic vaccines for cancer: an overview of clinical trials | Q38227030 |
| | Tumor-associated macrophages: from mechanisms to therapy | Q38230880 |
| | Polymer multilayer tattooing for enhanced DNA vaccination | Q38499608 |
| | In Vivo Enrichment of Diabetogenic T Cells | Q38708157 |
| | Biomaterials for enhancing anti-cancer immunity | Q38741829 |
| | The future of cancer treatment: immunomodulation, CARs and combination immunotherapy | Q38775177 |
| | Dendritic cell-derived exosomes for cancer therapy | Q38795623 |
| | NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models | Q38797595 |
| | Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines. | Q38843395 |
| | Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. | Q38872918 |
| | Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity | Q38960525 |
| | Progress in tumor-associated macrophage (TAM)-targeted therapeutics | Q39267549 |
| | Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy | Q39271075 |
| | Delivering safer immunotherapies for cancer | Q39330984 |
| | Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake | Q39423946 |
| | Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy | Q39436858 |
| | Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity | Q39576961 |
| | Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. | Q39720586 |
| | In situ regulation of DC subsets and T cells mediates tumor regression in mice | Q39885761 |
| | Infection-mimicking materials to program dendritic cells in situ | Q39896570 |
| | Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy | Q40031017 |
| | Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs | Q40089449 |
| | A STING-activating nanovaccine for cancer immunotherapy | Q40230470 |
| | Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. | Q40309343 |
| | Coley's toxins, tumor necrosis factor and cancer research: a historical perspective | Q40510386 |
| | In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity | Q40937108 |
| | CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses | Q41736997 |
| | Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging | Q41758345 |
| | Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer | Q42958489 |
| | CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. | Q43899944 |
| | A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells | Q44356545 |
| | Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery | Q44438209 |
| | In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. | Q44490370 |
| | Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody | Q44863106 |
| | Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy | Q44873455 |
| | Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases | Q45864268 |
| | Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles | Q46574650 |
| | Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. | Q46798411 |
| | Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy | Q47193084 |
| P433 | issue | 9 | |
| P304 | page(s) | 761-772 | |
| P577 | publication date | 2018-08-13 | |
| P1433 | published in | Nature Materials | Q1998645 |
| P1476 | title | Biomaterial-assisted targeted modulation of immune cells in cancer treatment | |
| P478 | volume | 17 | |